Bart Van Hooland
Droia Ventures is a specialist oncology-only investor, dedicated to making an impact and save patient lives. Bart Van Hooland was Managing Partner from its establishment in 2012 until 2018. He has invested with the likes of GV, Venrock, The Column Group, Invus and others. He was Founding CEO of Tusk Therapeutics (acquired for € 655M by Roche in 2018) TCR T-cell pioneering Pact Pharma, Arcus Biosciences and Cyteir.
Van Hooland graduated as an engineer from the University of Ghent and has an MBA from INSEAD. He started his career at BCG in Paris. After BCG he was a hands-on investor in small to midsize companies in different industries.
He is a parting member of the board of directors of Gimv, a Euronext listed private equity and venture capital investor. He is on advisory boards of the Hermes Fund and of PMV, the investment company of the Flemish government.
In addition to the immense promise of biotechnology still ahead of us, building bridges between China and Europe, tech infrastructure, the intersection between health, biotech and food are some of the things that get him quite excited these days.